Can-Fite BioPharma Ltd. (CANF)
NYSEAMERICAN: CANF · IEX Real-Time Price · USD
2.380
+0.143 (6.37%)
May 17, 2024, 4:00 PM EDT - Market closed

Can-Fite BioPharma Income Statement

Millions ILS. Fiscal year is Jan - Dec.
Year 20232022202120202019 2018 - 2010
Revenue
0.740.810.850.762.03
Upgrade
Revenue Growth (YoY)
-8.27%-5.04%11.80%-62.45%-46.81%
Upgrade
Gross Profit
0.740.810.850.762.03
Upgrade
Selling, General & Admin
2.963.143.852.953.06
Upgrade
Research & Development
5.987.769.8511.9510.98
Upgrade
Operating Expenses
8.9410.9113.714.914.04
Upgrade
Operating Income
-8.2-10.1-12.84-14.14-12.01
Upgrade
Other Expense / Income
-0.560.08-0.230.30.62
Upgrade
Pretax Income
-7.63-10.17-12.62-14.44-12.63
Upgrade
Net Income
-7.63-10.17-12.62-14.44-12.63
Upgrade
Preferred Dividends
002.590.720
Upgrade
Shares Outstanding (Basic)
1,27881655335886
Upgrade
Shares Outstanding (Diluted)
1,27881655335886
Upgrade
Shares Change
56.71%47.49%54.31%317.19%120.84%
Upgrade
EPS (Basic)
-3.00-3.00-9.00-12.00-42.00
Upgrade
EPS (Diluted)
-3.00-3.00-9.00-12.00-42.00
Upgrade
Free Cash Flow
-8.44-10.81-9.87-12.09-11.09
Upgrade
Free Cash Flow Per Share
-1.98-3.98-5.35-10.12-38.72
Upgrade
Gross Margin
100.00%100.00%100.00%100.00%100.00%
Upgrade
Operating Margin
-1102.96%-1246.42%-1505.51%-1853.08%-590.90%
Upgrade
Profit Margin
-1027.46%-1255.93%-1478.90%-1892.92%-621.31%
Upgrade
Free Cash Flow Margin
-1136.20%-1334.57%-1156.98%-1584.40%-545.62%
Upgrade
EBITDA
-7.53-10.11-12.55-14.42-12.61
Upgrade
EBITDA Margin
-1012.79%-1247.53%-1470.81%-1890.17%-620.62%
Upgrade
Depreciation & Amortization
0.110.070.070.020.01
Upgrade
EBIT
-7.63-10.17-12.62-14.44-12.63
Upgrade
EBIT Margin
-1027.46%-1255.93%-1478.90%-1892.92%-621.31%
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).